Additional clinical parameters such as Ki-67 proliferative index or expression levels of hormone receptor, which represent tumor biology or subtype, may provide additional information to aid a treatment decision for this subgroup of breast cancer patients [14, 15]. This evidence concerns the gene NR4A1 and breast carcinoma.